Rezolute's CEO Took Home $5,711,410 And Also Chairs The Board, Proxy Shows
The annual proxy lists Nevan Elam as CEO and acting chairman, with a vote on more authorized shares set for December 2.
Rezolute CEO Nevan Charles Elam received $5,711,410 in total compensation, according to the pay table in the company's annual proxy filing dated Wednesday. The same filing shows he is also acting chairman of the board, while stockholders are asked to approve an increase in authorized shares.
One person, two seats
Elam has been CEO since January 2013 and acting chair of the board since May 2022, the proxy says. Young-Jin Kim, who now sits as a director, chaired the board until May 2022.
The board says it has no policy on whether one person should hold both the CEO and chairman jobs. It says it wants flexibility to decide "at any given point in time" what provides appropriate leadership.
There are seven directors, and five are independent under Nasdaq rules. Elam and Kim are the two who are not. Kim is Chairman and CEO of Handok, a pharmaceutical company in Korea, and the board has one observer, So-Hyun Kwon, a representative of Handok.
The ballot
Stockholders vote at a virtual annual meeting on Wednesday, December 2, 2026, at 3:00 p.m. Pacific Time. All seven directors are nominated for re-election, and the proxy says no stockholder has nominated anyone.
The ballot also carries the shareholder vote on executive pay, the Share Increase Proposal (Proposal 4) and an Adjournment Proposal (Proposal 5). Management recommends the share increase and adjournment items. The share increase is the item that changes what each existing share represents.
The proxy also covers the auditor ratification as Proposal 2.
How the board worked
The board met seven times in the fiscal year ended June 30, 2026, and every director attended at least 75% of the meetings of the board and the committees they served on. The audit committee met four times and the compensation committee three times.
Gil Labrucherie chairs the audit committee. Wladimir Hogenhuis, M.D., chairs the compensation committee, and Nerissa Kreher, M.D., chairs the nominating and governance committee.
Voting runs through the December 2 meeting, where the share increase and the re-election of a CEO who also leads the board are on the same ballot.
Sources
- Rezolute — DEF 14A (2026-10-21) — SEC EDGAR